The Data Mouse that Aurora'd: EntreMed Preclinicals Uplifting
Published results from preclinical work with the company's oral Aurora A angiogenic kinase inhibitor boosted shares of EntreMed Inc., leaving the stock (NASDAQ:ENMD) to close Monday at $1.73, up 34 cents, or 24.5 percent, after trading as high as $1.99.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.